Antiphospholipid Antibodies in Severe COVID-19: Frequency, Clinical Features, and 12-Week Follow-Up
We detected APLAs in one third of patients with severe COVID-19; however, they were not associated with clinical thromboembolic events and decreased markedly over time. These findings indicate that APLA responses during acute COVID-19 are largely transient and may not be useful for predicting thrombotic risk. Our findings do not support routine APLA testing during the acute phase of COVID-19.
Authors
- Chowdhury Adnan Sami (ORCID: https://orcid.org/0000-0001-6816-4085)
- Kazi Mohammad Kamrul Islam (ORCID: https://orcid.org/0000-0001-9298-0023)
- Md. Tanvir Islam (ORCID: https://orcid.org/0000-0002-8604-1035)
- Md. Nazmul Hasan
- Fazle R Chowdhury
Institutions
- Bangladesh Medical University (BD)
- University of Dhaka (BD)
- Dhaka Medical College and Hospital (BD)
Publication Details
- Journal
- Cureus
- Published
- 2026-01-03
- DOI
- https://doi.org/10.7759/cureus.100657
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00